Free tool
Rare disease stocks
We cover 25 companies grouped under the Rare disease theme. The median market value in the group is $98.59M. Across the group, the median move over the past trading day is +1.61%. 43% of the 23 with a 200-day average trade above it. Price change over the past year runs from −52.3% to +83.4% across the middle 80 percent of the group, with a median of −8.7%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
25 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated | 475.00 EUR | +10.21% | +23.55% | +41.64% |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | 204.00 EUR | −19.59% | −40.19% | −10.21% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | 52.70 EUR | +2.53% | +10.68% | +1.80% |
| ABVX.PA | ABIVAX Société Anonyme | 102.30 EUR | −5.63% | −11.04% | +48.91% |
| CAMX.ST | Camurus AB (publ) | 615.00 SEK | −1.68% | +0.49% | −15.35% |
| DBV.PA | DBV Technologies S.A. | 2.53 EUR | +5.42% | −22.51% | +60.13% |
| GNFT.PA | Genfit S.A. | 14.30 EUR | +5.30% | +172.38% | +310.45% |
| AYJ.DE | Valneva SE | 2.98 EUR | +35.29% | −23.93% | −21.89% |
| XUP.DE | Genfit S.A. | 14.08 EUR | −1.81% | +164.41% | +166.82% |
| CRNO-B.ST | Cereno Scientific AB (publ) | 4.71 SEK | +0.13% | −32.04% | −53.59% |
| ABNX.PA | ABIONYX Pharma SA | 1.97 EUR | +5.79% | −49.58% | −31.34% |
| STX.L | Shield Therapeutics plc | 4.85 GBP | −15.65% | −50.76% | −37.42% |
| ALTHX.PA | THX Pharma Société Anonyme | 4.18 EUR | +5.16% | +83.92% | +73.96% |
| IMM.L | ImmuPharma plc | 3.41 GBP | −24.22% | −45.00% | +89.66% |
| ALDVI.PA | Advicenne S.A. | 1.75 EUR | +4.79% | −6.02% | +39.11% |
| ALBPS.PA | Biophytis S.A. | 0.08 EUR | +422.88% | +28.41% | −50.31% |
| ANNX.ST | Annexin Pharmaceuticals AB (publ) | 13.60 SEK | +7.09% | −31.66% | −46.03% |
| PHR.WA | Pharmena S.A. | 3.14 PLN | +1.62% | +18.49% | −8.72% |
| BIOSGN.ST | Biosergen AB (publ) | 2.48 SEK | +262.31% | −93.80% | −94.62% |
| APTA.ST | Aptahem AB (publ) | 0.56 SEK | −15.96% | −51.69% | −67.65% |
| ALNEV.PA | Neovacs S.A. | 0.55 EUR | −31.22% | +6150.00% | −11.29% |
| BIOV.SW | BioVersys AG | 25.20 CHF | −6.67% | +6.33% | −9.03% |
| BSLN.SW | Basilea Pharmaceutica AG | 65.30 CHF | +24.62% | +19.82% | +40.88% |
| CURN.SW | Curatis Holding AG | 19.00 CHF | −11.21% | +45.59% | +65.22% |
| SANN.SW | Santhera Pharmaceuticals Holding AG | 15.70 CHF | +9.79% | +29.32% | +13.44% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.